An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab, Valaciclovir and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.

  • Fleming, Shaun (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Effective start/end date7/08/1931/12/24


  • Malignant Haematology
  • B-Cell Lymphoma
  • Clinical trial